Trial Profile
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacterial infections; Gram-positive infections
- Focus Pharmacokinetics
- Acronyms ORKIDS
- Sponsors Melinta Therapeutics
- 01 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 13 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 13 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.